NanoViricides, Inc. Reports Dramatically Extended Survival for FluCide™ Treated Animals in an Influenza Lethality Study
WEST HAVEN, Conn.--(BUSINESS WIRE)-- NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company") reported today that its FluCide™ drug candidates demonstrated dramatically improved survival in animals administered a lethal dose of influenza virus. Animals treated with all of the different influenza nanoviricide drug candidates survived for dramatically longer periods as compared to Tamiflu® treated animals.
Animals treated with the best of the optimized FluCide nanoviricide drug candidates survived greater than twice as long (18.1 days) as opposed to the animals treated with Tamiflu (only 7.8 days). In a previous study, the Company had reported that animals treated with the then best anti-influenza nanoviricides survived for as long as 13.9 days in the same animal model.
We are extremely happy with the substantially improved performance achieved in our optimization efforts,” said Randall Barton, PhD, Chief Scientific Officer of the Company, adding, “An increase in dosage is now likely to lead to total survival even in this completely lethal virus challenge model.”
“Our Influenza Program is progressing satisfactorily towards a pre-IND submission to the FDA in the near future,” said Eugene Seymour, MD, MPH, CEO of the Company.
Comment: It would be nice to see the stock pop, even double on this news, but whatever it does matters less then the significance of this development. Put away your trading hat for a moment, no, put it back on, and realize how this relates to NNVC's progress from a speculative, unheard of, shot in the dark biotechnology company to becoming one of the big boys on the block.
A
